BioNTech Narrows FY26 Revenue Outlook Guidance Range

MT Newswires · 4d ago
07:23 AM EST, 11/03/2026 (MT Newswires) -- BioNTech (22UA.F) upgraded its non-IFRS revenue guidance for full-year 2026 with its latest earnings update, according to a Tuesday filing. The German drugmaker expects revenue for the year ending Dec. 31 of between 1.70 billion euros and 1.90 billion euros, compared with its previous outlook of 1.60 billion euros to 1.90 billion euros.